Clinical Trials Logo

Resectable Esophageal Cancer clinical trials

View clinical trials related to Resectable Esophageal Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05307835 Recruiting - Clinical trials for Resectable Esophageal Cancer

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Start date: December 2, 2021
Phase: Phase 1
Study type: Interventional

This research study is evaluating a new type of esophagus cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for esophagus cancer patients who have completed adjuvant therapy following neoadjuvant therapy and surgical resection. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of resectable esophagus cancer, so as to provide a new personalized therapeutic strategy.

NCT ID: NCT04006041 Recruiting - Clinical trials for Resectable Esophageal Cancer

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Start date: June 25, 2019
Phase: Phase 2
Study type: Interventional

Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal cancer (EC). However, only 20% to 40% of EC patients can achieve pathologic complete response (pCR) after neoadjuvant CRT with favorable prognosis. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the combination of toripalimab (an anti-PD-1 antibody) combined with neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (ESCC).